DK0509019T3 - Behandling af humane retrovirale infektioner med 2',3'-dideoxyinosin - Google Patents

Behandling af humane retrovirale infektioner med 2',3'-dideoxyinosin

Info

Publication number
DK0509019T3
DK0509019T3 DK91902028T DK91902028T DK0509019T3 DK 0509019 T3 DK0509019 T3 DK 0509019T3 DK 91902028 T DK91902028 T DK 91902028T DK 91902028 T DK91902028 T DK 91902028T DK 0509019 T3 DK0509019 T3 DK 0509019T3
Authority
DK
Denmark
Prior art keywords
dideoxyinosine
treatment
retroviral infections
human retroviral
human
Prior art date
Application number
DK91902028T
Other languages
Danish (da)
English (en)
Inventor
Robert Yarchoan
Samuel Broder
Hiroaki Mitsuya
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of DK0509019T3 publication Critical patent/DK0509019T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DK91902028T 1990-01-03 1991-01-03 Behandling af humane retrovirale infektioner med 2',3'-dideoxyinosin DK0509019T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/460,490 US5026687A (en) 1990-01-03 1990-01-03 Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
PCT/US1991/000005 WO1991009605A1 (en) 1990-01-03 1991-01-03 Treatment of human retroviral infections with 2',3'-dideoxyinosine

Publications (1)

Publication Number Publication Date
DK0509019T3 true DK0509019T3 (da) 1999-04-19

Family

ID=23828916

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91902028T DK0509019T3 (da) 1990-01-03 1991-01-03 Behandling af humane retrovirale infektioner med 2',3'-dideoxyinosin

Country Status (10)

Country Link
US (2) US5026687A (de)
EP (1) EP0509019B1 (de)
JP (1) JP2829545B2 (de)
AT (1) ATE168268T1 (de)
AU (1) AU643976B2 (de)
CA (1) CA2072573C (de)
DE (1) DE69129800T2 (de)
DK (1) DK0509019T3 (de)
ES (1) ES2125233T3 (de)
WO (1) WO1991009605A1 (de)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254539A (en) * 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
DE3872635T2 (de) * 1987-04-09 1992-12-17 Fisons Plc Pentamidin enthaltende pharmazeutische zusammensetzungen.
JPH02204489A (ja) * 1989-02-02 1990-08-14 Ajinomoto Co Inc 易溶性２’，３’―ジデオキシイノシン、その製造法及び２’，３’―ジデオキシイノシン水性溶液の製造法
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5162361A (en) * 1990-04-10 1992-11-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of treating diseases associated with elevated levels of interleukin 1
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
US5231174A (en) * 1992-02-27 1993-07-27 University Of Iowa Research Foundation 2'isodideoxy-β-D-nucleosides as stable antiviral agents
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
ATE273700T1 (de) * 1993-05-21 2004-09-15 Us Gov Health & Human Serv Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren
EP0631783A1 (de) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antivirale Kombinationen von 2',3-Di-deoxyribonukleosiden mit 6-benzyl-1-ethoxy-methyl-5-substituierten Uracil-Derivaten
US6093702A (en) * 1993-12-20 2000-07-25 The United States Of America As Represented By The Department Of Health And Human Services Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
US6130036A (en) * 1994-02-18 2000-10-10 University Of Washington Methods and compositions for screening for anti-AIDS drugs
US6338963B1 (en) 1994-07-25 2002-01-15 Neotherapeutics, Inc. Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
EP1852121A3 (de) 1994-08-29 2007-11-21 Wake Forest University Flüssige Analoge zur Behandlung viraler Infektionen
US7135584B2 (en) * 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US20020058636A1 (en) * 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US20030180254A1 (en) * 1995-05-26 2003-09-25 The Govt. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5840711A (en) * 1995-06-21 1998-11-24 University Of Kentucky Research Foundation Compositions containing lithium inorganic salts and anti-viral drugs and method of treating viral infections such as acquired immunodeficiency syndrome
CA2329474C (en) 1995-11-02 2002-02-26 Schering Corporation Continuous low-dose cytokine infusion therapy
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US6528098B2 (en) * 1996-10-22 2003-03-04 Advanced Viral Research Corp. Preparation of a therapeutic composition
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
US6114312A (en) * 1997-03-07 2000-09-05 Research Institute For Genetic And Human Therapy (R.I.G.H.T.) Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
KR100220645B1 (ko) * 1997-07-04 1999-09-15 구광시 벤젠유도체의 제조방법
US6800616B2 (en) * 1998-02-26 2004-10-05 Supergen, Inc. Treatment of HIV infections
AU3786299A (en) 1998-05-04 1999-11-23 Neotherapeutics, Inc. Novel serotonin-like 9-substituted hypoxanthine and methods of use
WO2000016625A1 (en) * 1998-09-23 2000-03-30 University Of Kentucky Research Foundation Antiviral drug compositions containing lithium inorganic salts
WO2001012228A2 (en) 1999-08-13 2001-02-22 University Of Maryland Biotechnology Institute Compositions for treating viral infections, and methods therefor
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US6288069B1 (en) 1999-11-16 2001-09-11 Neotherapeutics, Inc. Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
US6407237B1 (en) 2001-02-21 2002-06-18 Neotherapeutics, Inc. Crystal forms of 9-substituted hypoxanthine derivatives
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US6849735B1 (en) 2000-06-23 2005-02-01 Merck Eprova Ag Methods of synthesis for 9-substituted hypoxanthine derivatives
ATE499103T1 (de) 2000-07-07 2011-03-15 Spectrum Pharmaceuticals Inc Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen
PT1411954E (pt) 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
WO2002048165A2 (en) * 2000-12-15 2002-06-20 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
US6759427B2 (en) 2001-04-20 2004-07-06 Spectrum Pharmaceuticals, Inc. Synthesis and methods of use of tetrahydroindolone analogues and derivatives
WO2002096826A2 (en) * 2001-05-29 2002-12-05 Koninklijke Philips Electronics N.V. Metal-ceramic bond
ES2358187T3 (es) * 2001-07-10 2011-05-06 JOHNSON & JOHNSON RESEARCH PTY LIMITED Procedimientos para la modificación genética de las células progenitoras hematopoyéticas y utilizaciones de las células modificadas.
US20030055249A1 (en) * 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
JP4714413B2 (ja) * 2001-08-31 2011-06-29 トムソン ライセンシング オーディオビジュアルストリームのためのシーケンスカウンタ
JP2005504087A (ja) * 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
KR20040094692A (ko) * 2002-02-14 2004-11-10 파마셋, 리미티드 변형된 불소화 뉴클레오사이드 유사체
EP2799442A1 (de) 2002-06-28 2014-11-05 IDENIX Pharmaceuticals, Inc. Modifizierte 2'- und 3'-Nukleosid-Prodrugs zur Behandlung von Flaviridae-Infektionen
BR0313164A (pt) * 2002-08-01 2007-07-17 Pharmasset Inc compostos com o sistema biciclo[4.2.1] nonano para o tratamento de infecções por flaviviridae
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
ES2586668T3 (es) 2003-05-30 2016-10-18 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
AU2004258750A1 (en) * 2003-07-25 2005-02-03 Centre National De La Recherche Scientifique -Cnrs Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis C
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
US20060040944A1 (en) * 2004-06-23 2006-02-23 Gilles Gosselin 5-Aza-7-deazapurine derivatives for treating Flaviviridae
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
MX2007003085A (es) * 2004-09-14 2007-08-02 Pharmasset Inc Preparacion de 2'-fluoro-2'-alquilo sustituido u otras ribofuranosil pirimidinas y purinas opcionalmente sustituidas y sus derivados.
AU2005332686B2 (en) * 2005-06-03 2012-09-27 Ohr Pharmaceutical, Inc. Methods for providing palliative care with AVR118
NZ571826A (en) 2006-04-11 2012-01-12 Novartis Ag HCV/HIV inhibitors and their uses
EP2068906B1 (de) 2006-09-19 2012-08-01 Sungkyunkwan University Foundation for Corporate Collaboration Antivirales mittel gegen tierische viren
AU2008219622A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
KR20110065440A (ko) 2008-07-02 2011-06-15 아이데닉스 파마슈티칼스, 인코포레이티드 바이러스 감염의 치료를 위한 화합물 및 제약 조성물
EP2376514A2 (de) * 2008-12-23 2011-10-19 Pharmasset, Inc. Nukleosidanaloga
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
MX2011006891A (es) * 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
EP2403860B1 (de) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene und phosphothiazole als hcv polymerase inhibitoren
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
CN102822175A (zh) 2009-12-18 2012-12-12 埃迪尼克斯医药公司 5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂
AU2011235112B2 (en) 2010-03-31 2015-07-09 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
MX2012011222A (es) 2010-04-01 2013-01-18 Centre Nat Rech Scient Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
MX2013003945A (es) 2010-10-08 2013-06-05 Novartis Ag Formulaciones de vitamina e como inhibidoras de sulfamida ns3.
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
WO2012107584A1 (en) 2011-02-11 2012-08-16 Universite Pierre Et Marie Curie (Paris 6) Methods for predicting outcome of a hepatitis virus infection
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
CA2843495A1 (en) 2011-08-03 2013-02-07 Cytheris Hcv immunotherapy
WO2013039920A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
WO2013039855A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
NZ623396A (en) 2011-09-16 2016-07-29 Gilead Pharmasset Llc Methods for treating hcv
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CH707029B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN104185420B (zh) 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
US20130217644A1 (en) 2012-02-13 2013-08-22 Idenix Pharmaceuticals, Inc. Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
EP2852605B1 (de) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclische phosphat-prodrugs für hcv-infektion
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
GEP201706723B (en) 2012-10-08 2017-08-25 Idenix Pharmaceuticals Llk 2'-chloro nucleoside analogs for hcv infection
WO2014063019A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
LT2950786T (lt) 2013-01-31 2020-03-10 Gilead Pharmasset Llc Dviejų antivirusinių junginių preparatų kompozicija
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (de) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thionukleoside zur behandlung von hcv
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
NZ716840A (en) 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015066370A1 (en) 2013-11-01 2015-05-07 Idenix Pharmaceuticals, Inc. D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
WO2015081297A1 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US10683321B2 (en) 2013-12-18 2020-06-16 Idenix Pharmaceuticals Llc 4′-or nucleosides for the treatment of HCV
EP3114122A1 (de) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Feste formen einer flaviviridae-virus-hemmerverbindung und salze davon
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
EP3927710A4 (de) * 2019-03-08 2022-12-21 University of Virginia Patent Foundation Zusammensetzungen und verfahren zur behandlung oder prävention von morbus alzheimer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
JPS621284A (ja) * 1985-03-28 1987-01-07 Masayoshi Umeno 高速応答性可視発光ダイオ−ド
ATE108794T1 (de) * 1985-05-15 1994-08-15 Wellcome Found Therapeutische nucleoside und deren herstellung.
AU570853B2 (en) * 1985-08-26 1988-03-24 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Inhibition of infectivity and cytopathic effect of htlv-111/ lav by purine bases
US4704357A (en) * 1985-09-30 1987-11-03 United States Of America As Represented By The Department Of Health And Human Services Immortalized T-lymphocyte cell line for testing HTLV-III inactivation
CA1327000C (en) * 1987-08-07 1994-02-15 David L.J. Tyrrell Antiviral therapy for hepatitis b
ATE79034T1 (de) * 1987-10-14 1992-08-15 Ueno Seiyaku Oyo Kenkyujo Kk Behandlung von viruskrankheiten.
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds

Also Published As

Publication number Publication date
WO1991009605A1 (en) 1991-07-11
EP0509019B1 (de) 1998-07-15
ATE168268T1 (de) 1998-08-15
EP0509019A1 (de) 1992-10-21
ES2125233T3 (es) 1999-03-01
DE69129800D1 (de) 1998-08-20
AU7175791A (en) 1991-07-24
JPH05506007A (ja) 1993-09-02
CA2072573C (en) 1996-05-28
JP2829545B2 (ja) 1998-11-25
DE69129800T2 (de) 1999-09-23
EP0509019A4 (en) 1993-03-24
US5026687A (en) 1991-06-25
CA2072573A1 (en) 1991-07-04
US5376642A (en) 1994-12-27
AU643976B2 (en) 1993-12-02

Similar Documents

Publication Publication Date Title
DK0509019T3 (da) Behandling af humane retrovirale infektioner med 2',3'-dideoxyinosin
DK198791D0 (da) Terapeutiske kombinationer af 3'-azido-3'-desoxythymidin og andre terapeutiske midler
DK162965C (da) Anvendelse af et difluornucleosid eller et farmaceutisk acceptabelt salt deraf til fremstilling af et laegemiddel til behandling af neoplasma
NO870241L (no) Hypoglykemiske tiazolidindioner.
DK524788D0 (da) Anvendelse af morphin-antagonister til fremstilling af laegemidler med immunomodulerende og antiviral effekt, isaer til behandling af erhvervede immundefekt-tilstande
FI923357A (fi) Framstaellning av fettsyramediciner
LU88790I2 (fr) Moxidectin et ses dérivés pharmaceutiquement acceptables
DK422589D0 (da) Farmaceutisk praeparat til behandling af immundefekttilstande
FI851261L (fi) Substituerade bensopyraner, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
ES2058343T3 (es) Piridinas disubstituidas.
DK0476113T3 (da) Lægemiddel til behandling af hyperlipidæmi og/eller atherosklerose
NO892505D0 (no) Behandling av vandige dispersjoner.
FI922428A0 (fi) Nya 2-amino-5-cyan-1,4- dihydropyridiner, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
DK101197A (da) Medikament til behandling af thrombocytopenia
NO881768D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksaner.
DK435089A (da) Anvendelse af zofenopril til behandling af rheumatoid arthritis
DK0393530T3 (da) 5,11-Dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-oner og -thioner og deres anvendelse til forebyggelse eller behandling af AIDS
NO890245L (no) Isoxazoler med nootrop aktivitet.
DE3780157T2 (de) Verwendung von 4-butyl-1,2-diphenyl-pyrazolidin-3,5-dion als antivirales arzneimittel gegen aids.
KR900007413A (ko) 에이즈 발병방지, 치료제 및 그 치료용 조성물
NO905643D0 (no) Fremgangsmaate for behandling av manganslam.
NO882279D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive endo-bicyklo (2,2,1) heptyl-adenosin-derivater.
NO900044D0 (no) Hemorroidale, andre blandinger og metoder for behandling.
NO894476D0 (no) Derivater av 2,3-difluorhydrokinon.
DK156052C (da) Fremgangsmaade til fremstilling af n,n,n',n'-tetraacetylethylendiamin